A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)

To compare overall survival between the ASA404 plus docetaxel group and the placebo plus docetaxel group

Patients with stage IIIb/IV NSCLC of all histologies, who have progressed while on or following a first-line chemotherapy regimen and are eligible for second-line line chemotherapy

Kusajili – Centralise les essais cliniques mondiaux